Currently, Biological E has 200 million doses of its COVID-19 vaccine Corbevax, while Bharat Biotech has a stockpile of 50 million doses of Covaxin.
According to news agency PTI, two major vaccine manufacturing units based in Hyderabad, Biological E and Bharat Biotech, are together preparing about 250 million Covid vaccine doses as and when orders are received.
At present, Biological E has 200 million doses of its COVID-19 vaccine Corbevax, while Bharat Biotech has a stockpile of 50 million doses of Covaxin, according to company sources concerned.
Dr Vikram Paradkar, executive vice-president (manufacturing) of Biologic E, said the firm produced a total of 30 crore doses of Corbevax, following a commitment to manufacture the vaccine for the central government, as reported by PTI.
In March 2022, Biological E successfully supplied 100 million doses to the government.
“We have around 20 crore (200 million) doses which are fully tested and ready to supply, as and when we receive orders. Additionally, we have manufactured 20 crore doses of antigen equivalent which Will help us accelerate the manufacturing of the finished Corbewax product quickly," Paradkar told PTI.
Biological E has developed the vaccine in collaboration with the Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine (Baylor), Houston, Texas, USA.
He further said that Biological E can start with additional vaccine supplies within eight weeks of future orders and as per its qualified manufacturing capacity can manufacture and supply around 100 million doses of Corbevax on a monthly basis.
Company sources said, “Bharat Biotech has readily available over 50 million doses of Covaxin in vials, and over 200 million doses in drug substance form. Additional production capacity is also being built to meet the demand for the product. is available." Available and ready to supply.
Covaxin, India's indigenous Covid-19 vaccine, was developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
Sources had earlier said that the production of Covaxin started earlier this year due to lack of demand for the product, and the 50 million doses in vials are also due to expire by early 2023, resulting in losses for the company.
No comments:
Post a Comment